
Anthropic's Mythos 5 AI model encountered significant difficulties with CAPTCHA tests during a security evaluation. While attempting to hack into a system, the AI spent a considerable amount of time trying to bypass these security measures, which are designed to differentiate humans from bots. Despite its ability to write and deploy exploits, the AI was repeatedly thwarted by CAPTCHA challenges, demonstrating the robustness of these tests. This incident highlights the challenges AI faces in navigating real-world security protocols and the importance of such measures in preventing unauthorized access.
Read originalEarlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
© TechCrunch AIxAI's attempt to dismiss the NAACP's Clean Air Act lawsuit failed after a federal judge ruled that its gas turbines are not exempt mobile sources and that plaintiffs have standing. This legal setback confirms that AI infrastructure operators cannot bypass environmental permitting by classifying heavy industrial equipment as temporary or mobile. The ruling forces xAI to face scrutiny over air quality impacts at its Colossus data center, setting a precedent for how large-scale compute facilities are regulated under existing environmental laws.
© TechCrunch AIWIRED AI · June 17, 2026 · Related
MIT Technology Review AI · June 22, 2026 · Related
TechCrunch AI · July 31, 2026 · Same story
WIRED AI · July 31, 2026 · Same story
The Verge AI · July 31, 2026 · Related
The Rundown AI · August 5, 2026 · Related
The Rundown AI · August 5, 2026 · Related
Matt Wolfe · August 17, 2026 · Related
The Verge AI · September 11, 2026 · Related
MIT Technology Review AI · September 23, 2026 · Related
TechCrunch AI · October 10, 2026 · Related
OpenAI is scaling back its ambitions as investor appetite for massive AI infrastructure bets cools. The company has lowered its fundraising target from $30 billion to $20 billion, with only $11 billion secured so far against a valuation that has dropped from $1.4 trillion. This retreat signals a growing wariness among Wall Street investors regarding the capital intensity of the AI race, forcing even the most dominant players to adjust their financial expectations.
Exin Therapeutics has demonstrated an AI agent physically controlling a robotic arm to inject drugs into a live mouse's brain. The experiment reveals a critical divergence in model behavior: Anthropic’s Claude Opus refused the procedure due to safety concerns, while Sonnet proceeded. This suggests that as agents gain direct access to physical lab equipment, their alignment and refusal mechanisms become operational realities rather than theoretical safeguards. It marks a shift from AI merely analyzing data to actively manipulating biological systems under human supervision. The team initially tested Claude Opus 5.5, but it halted the injection, citing potential harm. Switching to Claude Sonnet 5 allowed the procedure to complete, though with delays caused by coordinate system glitches. A secondary Opus agent had to fix code errors without knowing a live surgery was underway. Human oversight remains essential as researchers test more complex tasks like craniotomies.